Literature DB >> 16301573

Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.

D A Heller1, C A Clifford, M H Goldschmidt, D E Holt, F S Shofer, A Smith, K U Sorenmo.   

Abstract

Cyclooxygenase-2 (COX-2) is an inducible member of the family of cyclooxygenase enzymes that has been implicated in the genesis of numerous cancers. The role of COX-2 in canine mammary neoplasia remains to be more clearly elucidated. The goal of the study reported here was to determine whether a direct association between levels of COX-2 expression and tumor histologic subtype exists in canine mammary carcinoma. Immunohistochemical analysis was performed using a polyclonal antiprostaglandin G/H synthase 2 IgG COX-2 antibody. Sections from the kidneys of young dogs, which stain positive for COX-2 in the macula densa, served as positive controls. Slides were reviewed by a single pathologist, and were evaluated for COX-2 expression according to previously established scales. Positive-staining tumors were given a COX-2 staining distribution (on the basis of the percentage of positive staining cells in five 400x fields) and intensity score according to previously established scales. The product of the COX-2 staining distribution and intensity scores was calculated to create a COX-2 staining index. COX-2 expression was detected in 28 of 50 (56%) samples evaluated. Anaplastic carcinomas had a significantly higher COX-2 staining distribution, intensity, and index, compared with those for adenocarcinomas (P < 0.0001). The overall percentage of positive tumors (56%) was consistent with that of prior studies. To the authors' knowledge, these results indicate, for the first time, a direct association between COX-2 expression and tumor histologic subtype in canine mammary carcinomas. Future research directed at measuring tumor response in canine mammary carcinoma patients treated with a selective COX-2 inhibitor is indicated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301573     DOI: 10.1354/vp.42-6-776

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  5 in total

1.  Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.

Authors:  Carlos H de M Souza; Evandro Toledo-Piza; Renee Amorin; Andrigo Barboza; Karen M Tobias
Journal:  Can Vet J       Date:  2009-05       Impact factor: 1.008

2.  The potential role of COX-2 in cancer stem cell-mediated canine mammary tumor initiation: an immunohistochemical study.

Authors:  Jian Huang; Di Zhang; Fuqiang Xie; Degui Lin
Journal:  J Vet Sci       Date:  2015-06-17       Impact factor: 1.672

3.  Identification of prognostic collagen signatures and potential therapeutic stromal targets in canine mammary gland carcinoma.

Authors:  Ashley Case; Becky K Brisson; Amy C Durham; Suzanne Rosen; James Monslow; Elizabeth Buza; Pascale Salah; Julie Gillem; Gordon Ruthel; Sridhar Veluvolu; Veronica Kristiansen; Ellen Puré; Dorothy C Brown; Karin U Sørenmo; Susan W Volk
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

4.  Collagen molecular phenotypic switch between non-neoplastic and neoplastic canine mammary tissues.

Authors:  Masahiko Terajima; Yuki Taga; Becky K Brisson; Amy C Durham; Kotaro Sato; Katsuhiro Uzawa; Tomoaki Saito; Shunji Hattori; Karin U Sørenmo; Mitsuo Yamauchi; Susan W Volk
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.996

Review 5.  In vitro comparative models for canine and human breast cancers.

Authors:  Simona Visan; Ovidiu Balacescu; Ioana Berindan-Neagoe; Cornel Catoi
Journal:  Clujul Med       Date:  2016-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.